Uric Acid and Multiple Myeloma, Unexplored Association
Yükleniyor...
Dosyalar
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Introduction: Multiple Myeloma (MM) is a common hematological malignancy and various factors affect survival. Uric acid (UA) is an easily and quickly accessible laboratory test. UA has been found to affect prognosis and survival in many hematological diseases and its impact on myeloma is not widely investigated. Methods: Our retrospective study includes 106 MM patients between 2014 and 2021. The influence of UA level at diagnosis on treatment outcomes and survival of patients who received autologous stem cell transplantation (ASCT) was investigated. Results: The mean UA at diagnosis was 6.05 mg/dL, and 38.7% of our cohort relapsed after a median of 30 months of follow-up, with 22.7% dead. In survival analysis, the level of UA did not significantly differ in both progression-free survival (PFS) and overall survival (OS) (HR, 1.067; 95% CI, 0.947-1.202; p=0.290, HR, 0.941; 95% CI, 0.791-1.121; p=0.497, respectively). Discussion and Conclusion: In our study, regardless of the cut-off value for the UA level at the time of diagnosis, the UA level had no impact on PFS or OS in MM patients who received ASCT.
Açıklama
Anahtar Kelimeler
Kaynak
ACTA ONCOLOGICA TURCICA
WoS Q Değeri
Scopus Q Değeri
Cilt
56
Sayı
1
